Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23542850 | 0.90 | MAPK14 (0.82) | MAPK14 | |
| SCHEMBL19367808 | 0.90 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL17542505 | 0.81 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL19367800 | 0.80 | MAPK14 (0.80) | MAPK14 | |
| SCHEMBL17542510 | 0.80 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL17552066 | 0.79 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL17542518 | 0.78 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL19349031 | 0.78 | MAPK14 (0.67) | MAPK14 | |
| SCHEMBL19367817 | 0.77 | MAPK14 (0.79) | MAPK14 | |
| SCHEMBL17542578 | 0.77 | MAPK14 (0.82) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186245-B1 | MAPK INHIBITORS | EverBrilliant Pharma Pty Ltd (AU) | 2021-06-23 | — | — | EP | disclosed |
| EP-3186245-B1 | MAPK INHIBITORS | EverBrilliant Pharma Pty Ltd (AU) | 2021-06-23 | — | — | EP | disclosed |
| US-20180289684-A1 | MAPK INHIBITORS | EverBrilliant Pharma Pty Ltd (AU) | 2018-10-11 | — | — | US | disclosed |
| US-20170266173-A1 | MAPK INHIBITORS | EVERBRILLIANT PHARMA PTY LTD. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20170266173-A1 | MAPK INHIBITORS | EVERBRILLIANT PHARMA PTY LTD. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20170266173-A1 | MAPK INHIBITORS | EVERBRILLIANT PHARMA PTY LTD. (AU) | 2017-09-21 | — | — | US | disclosed |
| WO-2016029263-A1 | MAPK INHIBITORS | WANG BING HUI (AU) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266173-A1 | MAPK INHIBITORS | MAPK1, MAPK4, MAPK3 | MAPK14 13/4885MAPK13 24/4885MAPK12 11/4885 |
| US-20180289684-A1 | MAPK INHIBITORS | MAPK1, MAPK4, MAPK3 | MAPK14 13/4885MAPK13 24/4885MAPK12 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.